LONDON (Reuters) – EU officials on Tuesday recommended that the two Omicron- tailored vaccines recently endorsed by the European Medicines Agency (EMA) be first deployed in high-risk individuals.
Developed by Moderna and the team of Pfizer and BioNTech, the new so-called bivalent shots combat the BA.1 version of Omicron and the original virus first detected in China.
(Reporting by Natalie Grover in London; Editing by Alex Richardson)
